Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy
Rejeski, Kai (German Cancer Consortium (DKTK))
Burchert, Andreas (Department of Internal Medicine, Hematology, Oncology and Immunology, Philipps University Marburg and University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany)
Iacoboni, Gloria (Universitat Autònoma de Barcelona. Departament de Medicina)
Sesques, Pierre (Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Pierre-Bénite, France)
Fransecky, Lars (Universitätsklinikum Schleswig-Holstein)
Bücklein, Veit (Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany)
Trenker, Corinna (Department of Internal Medicine, Hematology, Oncology and Immunology, Philipps University Marburg and University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany)
Hernani, Rafael (Hospital Clínic Universitari (València))
Naumann, Ralph (St. Marien-Krankenhaus Siegen (Siegen, Alemanya))
Schäfer, Jonas (Department of Internal Medicine, Hematology, Oncology and Immunology, Philipps University Marburg and University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany)
Blumenberg, Viktoria (German Cancer Consortium (DKTK))
Schmidt, Christian (Ludwig-Maximilians-Universitat Munchen. Department of Medicine)
Sohlbach, Kristina (Department of Internal Medicine, Hematology, Oncology and Immunology, Philipps University Marburg and University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany)
von Bergwelt-Baildon, Michael (German Cancer Consortium (DKTK))
Bachy, Emmanuel (Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Pierre-Bénite, France)
Barba, Pere (Universitat Autònoma de Barcelona. Departament de Medicina)
Subklewe, Marion (German Cancer Consortium (DKTK))

Date:	2022
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Published in:	Blood advances, Vol. 6 (august 2022) , p. 4719-4725, ISSN 2473-9537

DOI: 10.1182/bloodadvances.2022007776
PMID: 35793454

7 p, 884.3 KB

The record appears in these collections:
Articles > Research articles
Articles > Published articles